entertainment -WSS

entertainment

author：leisure time 2025-10-01 23:00:39 - browse：8197

Illustration of researchers working among oversized pill bottles, lab equipment, and medicine for story about the development of obesity medications – health and pharma coverage from STAT — Molly Ferguson for STAT

The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the blockbuster products.

Nearly 70 obesity treatments are in development, and about two-thirds use a similar mechanism as Wegovy and Mounjaro, according to the STAT Obesity Drug Tracker, a new database compiled by STAT. There are also a minority of companies pursuing entirely different approaches, hoping that they will stand out among the field.

The tracker, which will be updated with significant developments each quarter, gives a sense of what new mechanisms could hit the market, how they would be delivered, and which companies are running the most trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： WATCH: Why do bright lights make us see spots?

focus

explore

focus

WSS

Regeneron agrees to White House price limits on anti

Popular nasal decongestant doesn't actually relieve congestion

How AI can help patients find reliable information about doctors

Study on Amgen’s bispecific immunotherapy produces positive data

White House touts steps to stem shortages of cancer treatments

Roche drug slashes death risk in early

leisure time

entertainment

knowledge

Supreme Court strikes down use of affirmative action

ADCs take center stage as promising cancer treatments

Medicare proposal to cover medical devices draws a mixed reaction

WATCH: Why do bright lights make us see spots?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: Live from the 2023 STAT Summit

Trump demands the U.S. pay no more for drugs than other countries … again

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

The high cost of giving birth even with insurance

New weight loss drugs vying to be the next Wegovy or Mounjaro

focus

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Cassava Sciences’ Alzheimer’s clinical trials should be halted

FDA panel endorses Alnylam’s heart drug — after picking it apart

How medical schools plan to diversify without affirmative action

Study on Amgen’s bispecific immunotherapy produces positive data

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

explore

focus

focus